NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Glycotest, Inc.

Glycotest, Inc.

Private
PennsylvaniaHealthcare & Life Scienceshttps://glycotest.com/

Last Round

Seed Round

Jul 16, 2026

Est. Valuation

$25M

Total Funding Raised

$13.81M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Glycotest, Inc. is a diagnostics company that specializes in the commercialization of non-invasive blood tests for the early detection of liver cancers and fibrosis-cirrhosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

liver disease diagnosticshepatocellular carcinoma detectionHCCbiomarker blood testliquid biopsynon-invasive diagnosticslaboratory developed testsLDTliver fibrosiscirrhosis screeningprecision medicinediagnostic algorithmhepatologygastroenterologycancer surveillance

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Glycotest, Inc. Comparables

Compare Glycotest, Inc. with similar companies based on industry and business-model similarity.

Glycotest, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Helio Genomics
84%
Mursla Bio
82%
AGED Diagnostics
78%

Glycotest, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundJul 16, 2026
VC RoundJan 23, 2024
Convertible DebtMay 2, 2023
Series A ExtensionNov 21, 2019
Series AOct 22, 2018

Key People

Founding team and executive leadership

Charles Swindell

Chief Executive Officer And Board Member

Executive Team

Glycotest, Inc. Investors

Notable investors and investment history

Glycotest, Inc. investors
InvestorRounds
EMV CapitalSeries A Extension, VC Round, Series A, Seed Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors increased 118% MoM.

  • Jan 23, 2024

    $1M round with EMV Capital and Fosun Pharma.

Glycotest, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Glycotest, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Glycotest, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersPennsylvania
Employee Range2
Year Founded2012
Last FundingJul 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.